Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 287-298

  Fournier, Philipe ^a   Wilden, Holger ^a   Schirmacher, Volker ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Center of Immunology and Oncology (IOZK)   (Germany)

Author keywords

Cellular antiviral response; Cellular toxicity; Innate cellular response; Newcastle disease virus; Normal versus tumor cells; Oncolytic virus; RIG I; Safety; Tumor selectivity; Type I interferon; Virus replication

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON 4; BETA INTERFERON; INTERFERON RECEPTOR; MEMBRANE RECEPTOR; ONCOLYTIC VIRUS; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL KILLING; CELL PROTECTION; CONTROLLED STUDY; CYTOSOL; DRUG SAFETY; GENE DELETION; GENE PRODUCT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INFECTION RESISTANCE; MACROPHAGE; MOLECULAR RECOGNITION; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANIMALS; CELL LINE, TUMOR; DEAD-BOX RNA HELICASES; DISEASE RESISTANCE; HUMANS; INTERFERONS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEWCASTLE DISEASE; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; TRANSFECTION; VIRUS REPLICATION;

EID: 84455193926     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1222     Document Type: Article

References (55)

1. Eager RM and Nemunaitis J: Clinical development directions in oncolytic viral therapy. Cancer Gene Ther 18: 305-317, 2011.
2. Sinkovics JG and Horvath JC: Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 16: 1-15, 2000. (Pubitemid 30066477)
3. Alexander DJ: Newcastle disease virus - an avian paramyxovirus. In: Newcastle Disease. Kluwer Academic, Dordrecht, pp1-22, 1988.
4. Nagai Y, Hamaguchi M and Toyoda T: Molecular biology of Newcastle disease virus. Prog Vet Microbiol Immunol 5: 16-64, 1998.
5. Al-Garib SO, Gielkens AL, Gruys E, Peeters BP and Koch G: Tissue tropism in the chicken embryo of non-virulent and virulent Newcastle diseases strains that express green fluorescence protein. Avian Pathol 32: 591-596, 2003. (Pubitemid 38106431)
6. Peeters BP, De Leeuw OS, Koch G and Gielkens AL: Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73: 5001-5009, 1999. (Pubitemid 29246761)
7. Janke M, Peeters B, Zhao H, De Leeuw O, Moorman R, Arnold A, Ziouta Y, Fournier P and Schirrmacher V: Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol 33: 823-832, 2008.
8. Zhao H, Janke M, Fournier P and Schirrmacher V: Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Virus Res 136: 75-80, 2008.
9. Janke M, Peeters B, De Leeuw O, Moorman R, Arnold A, Fournier P and Schirrmacher V: Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther 14: 1639-1649, 2007. (Pubitemid 350143189)
10. Kawai T and Akira S: Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci 1143: 1-20, 2008.
11. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S and Fujita T: The RNA helicase RIG-I has an essential function in double-strand RNA-induced innate antiviral response. Nat Immunol 5: 730-737, 2004. (Pubitemid 39023305)
12. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S and Hartmann G: 5'-Triphosphate RNA is the ligand for RIG-I. Science 314: 994-997, 2006.
13. Pichlmair A, Schulz O, Tan CP, Näslund TI, Liljeström P, Weber F and Reis e Sousa C: RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 314: 997-1001, 2006. (Pubitemid 44749946)
14. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T and Akira S: Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105, 2006.
15. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O and Akira S: Cell type specific involvement of RIG-I in antiviral response. Immunity 23: 19-28, 2005. (Pubitemid 41019654)
16. Michallet MC, Meylan E, Ermolaeva MA, Vazquez J, Rebsamen M, Curran J, Poeck H, Bscheider M, Hartmann G, König M, Kalinke U, Pasparakis M and Tschopp J: TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity 28: 651-661, 2008.
17. Grandvaux N, Servant MJ, ten Oever B, Sen GC, Balachandran S, Barber GN, Lin R and Hiscott J: Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J Virol 76: 5532-5539, 2002. (Pubitemid 34517903)
18. Biron CA and Sen GC: Interferons and other cytokines. In: Fundamental Virology. Knipe DM and Howley PM (eds). Lippincott Williams and Wilkins, Philadelphia, PA, pp321-351, 2001.
19. Sen GC and Peters GA: Viral stress-inducible genes. Adv Virus Res 70: 233-263, 2007.
20. Dunn GP, Koebel CM and Schreiber RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836-848, 2006. (Pubitemid 44631652)
21. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R and Ertel C: Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 6: 63-73, 1999. (Pubitemid 29043695)
22. Wilden H, Fournier P, Zawatzky R and Schirrmacher V: Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle disease virus. Int J Oncol 34: 971-982, 2009.
23. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E and Siegal T: Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13: 221-228, 2006. (Pubitemid 41763501)
24. Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B and Csatary CM: MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 67: 83-93, 2004. (Pubitemid 38418253)
25. Lorence RM, Roberts MS, O'Neil JD, Groene WS, Miller JA, Mueller SN and Bamat MK: Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 7: 157-167, 2007. (Pubitemid 46348630)
26. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C and Heim MH: Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 85: 720-725, 2000. (Pubitemid 30080488)
27. Paucker K, Cantell K and Henle W: Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology 17: 324-334, 1962.
28. Pitha PM: Introduction: interferon's connection to cancer. Semin Cancer Biol 10: 69-72, 2000.
29. Stojdl DF, Lichty BD, ten Oever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J and Bell JC: VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275, 2003. (Pubitemid 37329791)
30. Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, Uddin S, Platanias LC and Rosen ST: Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 91: 570-576, 1998. (Pubitemid 28053380)
31. Wagner TC, Velichko S, Chesney SK, Biroc S, Harde D, Vogel D and Croze E: Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer 111: 32-42, 2004. (Pubitemid 38859280)
32. Krishnamurthy S, Takimoto T, Scroggs RA and Portner A: Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80: 5145-5155, 2006.
33. Fiola C, Peeters B, Fournier P, Arnold A, Bucur M and Schirrmacher V: Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 119: 328-338, 2006.
34. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM and Greager JA: Newcastle disease virus selectively kills human tumor cells. J Surg Res 52: 448-453, 1992.
35. Bar-Eli N, Giloh H, Schlesinger M and Zakay-Rones Z: Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. J Cancer Res Clin Oncol 122: 409-415, 1996. (Pubitemid 26226266)
36. Tzadok-David Y, Metzkin-Eizenberg M and Zakay-Rones Z: The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells. J Cancer Res Clin Oncol 121: 169-174, 1995.
37. Chen LL, Yang L and Carmichael GG: Molecular basis for an attenuated cytoplasmic dsRNA response in human embryonic stem cells. Cell Cycle 9: 3552-3564, 2010.
38. Lin R, Yang L, Nakhaei P, Sun Q, Sharif-Askari E, Julkunen I and Hiscott J: Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20. J Biol Chem 281: 2095-2103, 2006. (Pubitemid 43845798)
39. Moore CB, Bergstralh DT, Duncan JA, Lei Y, Morrison TE, Zimmermann AG, Accavitti-Loper MA, Madden VJ, Sun L, Ye Z, Lich JD, Heise MT, Chen Z and Ting JP: NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 451: 573-577, 2008. (Pubitemid 351186265)
40. Rajput A, Kovalenko A, Bogdanov K, Yang SH, Kang TB, Kim JC, Du J and Wallach D: RIG-I RNA helicase activation of IRF3 transcription factor is negatively regulated by caspase-8-mediated cleavage of the RIP1 protein. Immunity 34: 340-351, 2011.
41. Su ZZ, Sarkar D, Emdad L, Barral PM and Fisher PB: Central role of interferon regulatory factor-1 (IRF-1) in controlling retinoic acid inducible gene-I (RIG-I) expression. J Cell Physiol 213: 502-510, 2007. (Pubitemid 47509733)
42. Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S and Affabris E: IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res 22: 39-47, 2002. (Pubitemid 34161281)
43. Shmulevitz M, Pan LZ, Garant K, Pan D and Lee PW: Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling. Cancer Res 70: 4912-4921, 2010.
44. Childs K, Stock N, Ross C, Andrejeva J, Hilton L, Skinner M, Randall R and Goodbourn S: MDA-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 359: 190-200, 2007. (Pubitemid 46223502)
45. Picaud S, Bardot B, De Maeyer E and Seif I: Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res 22: 457-462, 2002. (Pubitemid 34579548)
46. Navarro S, Colamonici OR and Llombart-Bosch A: Immunohistochemical detection of the type I interferon receptor in human fetal, adult, and neoplastic tissues. Mod Pathol 9: 150-156, 1996. (Pubitemid 26090181)
47. Zhou R, Yazdi AS, Menu P and Tschopp J: A role for mitochondria in NLRP3 inflammasome activation. Nature 469: 221-225, 2011.
48. Koshiba T, Yasukawa K, Yanagi Y and Kawabata S: Mitochondrial membrane potential is required for MAVS-mediated antiviral signaling. Sci Signal 4: ra7, 2011.
49. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, Kim HP, Fitzgerald KA, Ryter SW and Choi AM: Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 12: 222-230, 2011.
50. Liu F and Gu J: Retinoic acid inducible gene-I, more than a virus sensor. Protein Cell 2: 351-357, 2011.
51. Loo YM and Gale M Jr: Immune signaling by RIG-I-like receptors. Immunity 34: 680-692, 2011.
52. Kübler K, Gehrke N, Riemann S, Böhnert V, Zillinger T, Hartmann E, Pölcher M, Rudlowski C, Kuhn W, Hartmann G and Barchet W: Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res 70: 5293-5304, 2010.
53. Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, Coch C, Janke M, Mihailovic A, Wardle G, Juranek S, Kato H, Kawai T, Poeck H, Fitzgerald KA, Takeuchi O, Akira S, Tuschl T, Latz E, Ludwig J and Hartmann G: Recognition of 5′ triphosphate by RIG-I helicase requires short blunt doublestranded RNA as contained in panhandle of negative-strand virus. Immunity 31: 25-34, 2009.
54. A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, Deniz J, Ramirez C, Díaz M, Gallardo G, De Galarreta CR, Salazar J, Lopez F, Edwards P, Parks J, Andujar M, Tontonoz P and Castrillo A: Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31: 245-258, 2009.
55. Fournier P, Arnold A, Wilden H and Schirrmacher V: Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol (In press).